Screener
CytomX Therapeutics CTMX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Amortization of intangible assets | 73 | 73 |
| Depreciation and amortization | 225 | 659 |
| Accretion of discounts on short-term investments | (2,154) | (851) |
| Stock-based compensation expense | 7,283 | 3,439 |
| Non-cash lease expense | 2,497 | 2,189 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | (35,481) | 1,234 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's accretion (amortization) of discounts and premiums, investments?
- CytomX Therapeutics (CTMX) reported accretion (amortization) of discounts and premiums, investments of $1.43M in Q2 2026.
- How has CytomX Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- CytomX Therapeutics's accretion (amortization) of discounts and premiums, investments increased by 259.7% year-over-year, from $397K to $1.43M.
- What is the long-term trend for CytomX Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), CytomX Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 66.5% compound annual growth rate (CAGR), from -$287K to $2.21M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric captures the non-cash adjustments to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts. It reflects the effective interest method applied to debt instruments held in the company's investment portfolio. This adjustment is necessary to reconcile net income with actual cash flows generated from investment activities.
Ask your AI about CytomX Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude